Welcome back to Stockhouse
Member Sign In

Email or Username:

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Enter your email address:
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

Get our best content in your email.

You are already a member! Please enter your password to sign in.
Quote  |  Bullboard  |  News  |  Opinion  |  Level II  |  Charts  |  Profile  |  Financials  |  Options  |  Price History  |  Analysts  |  Earnings  |  Insiders

NuPathe Inc PATH

Sector: Healthcare | Sub-Sector: Biotechnology

Price: N/A | Change: N/A | %Change: N/A
Volume: 0 | Day High/Low: N/A/N/A | 52 Week High/Low: 4.49/1.57
View modes: 
0 stars

Intellectual Property

NuPathe exclusively owns all worldwide rights to the migraine patch, with IP protection in the U.S. through 2027.  rate and reply
0 stars

NASDAQ Target for PATH

The NASDAQ target for PATH is $6.00 but with a yes vote from the FDA on January 17, this will need to be revised much higher.  rate and reply
0 stars

She's on the Move !

At this rate, today will be last chance to get in under $3.00. A superstar biotech in the make here.  rate and reply
0 stars

No Competitors

Very important to realize here that Nupathe will be the only patch delivery system of migrane medication on the market. The number of migrane suffers that need this treatment are in the millions more
0 stars

RE: $PATH Gaining Momentum

Cool. What is their price target? Personally I think this stock with break $10 on an FDA yes vote in January. I base this on the very low number of shares outstanding and valuations I have seen more
0 stars

31 Million Americans Affected

Over $14 billion spent on migranes annually in the US and Nupathe has proprietary delivery system that will target a good chunk of this huge pie. PDUFA date set at January 17, which means we more